Stage 3 study of Tazemetostat/placebo + Lenalidomide and Rituximab in Patients with FL

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04224493?term=A+Phase+1B%2F3+Double-Blind%2C+Randomized%2C+Active-Controlled%2C+3-Stage%2C+Biomarker+adaptive+study+of+Tazemetostat+or+placebo+in+combination+with+lenalidomide+plus+rituximab+in+subjects+with+relapsed%2Frefractory+Follicular+Lymphoma+%28EZH-302%29&draw=2&rank=1